Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian Clinics

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue SUPPL. 3, 2011, Pages

  Martins, Angelica N ^a,b   Arruda, Monica B ^a   Aleixo, Agdemir W ^c   Pires, Ana F ^a   Greco, Dirceu B ^c   De M Brindeiro, Rodrigo ^a   Tanuri, Amilcar ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NATIONAL CANCER INSTITUTE   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

drug resistance; etravirine; mutations; NNRTIs

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE;

ARTICLE; BRAZIL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; PREVALENCE; PRIORITY JOURNAL; SALVAGE THERAPY; SAMPLE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; BRAZIL; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MUTATION, MISSENSE; NEVIRAPINE; PREVALENCE; PYRIDAZINES;

EID: 79960790635     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31821e9cf6     Document Type: Article

References (10)

1. Wensing AM, van der Vijver DA, Angarano G, et al. Prevalence of drugresistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966. (Pubitemid 41266791)
2. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. Acquir Immune Defic Syndr. 2004;18: 1393-1401. (Pubitemid 38925131)
3. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4680-4686. (Pubitemid 39577672)
4. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001;26(suppl 1):S25-S33.
5. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet. 2007;370:29-38. (Pubitemid 47017466)
6. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet. 2007;370:39-48. (Pubitemid 47017467)
7. Vingerhoets J, Azijn H, Tambuyzer L, et al. Activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data. AIDS Res Hum Retroviruses. 2010;6:621-624.
8. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005;21:3797-3800. (Pubitemid 41535530)
9. Llibre JM, Santos JR, Puig T, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother. 2008;5:909-913.
10. Brenner B, Turner D, Oliveira M, et al. AV106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1-F5. (Pubitemid 36106291)